drugset / Trial / NCT05557903
Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
NaSequentialOpen-labelTreatment
Summary
Phase I clinical study of multicenter, single-arm, open, non-randomized evaluation of recombinant humanized anti-CD52 monoclonal antibody in the NHL and T-PLL
Timeline
- Start
- 2021-12-20
- Primary completion
- 2022-12-30
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant Humanized Anti-CD52 Monoclonal Antibody | Monoclonal antibody | — | — |